Tough blow for Novartis: General Court confirms that mark representing transdermal patch is invalid

European Union

The General Court has upheld a decision of the EUIPO finding that Novartis’ figurative EU trademark, which represents the company’s Exolon transdermal patch, was invalid. 

Unlock unlimited access to all WTR content